Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Climacteric ; 26(3): 284-288, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36912363

RESUMEN

OBJECTIVE: Overactive bladder (OAB) is a complex and multifactorial syndrome associated with urinary frequency, urgency and incontinence. The menopause-associated hormonal changes play a role in the development of this condition. Vaginal estrogens are effective in improving OAB in postmenopausal women (PMW) with vulvovaginal atrophy (VVA). Ospemifene is a selective estrogen receptor modulator licensed for the treatment of VVA. This study aimed to evaluate the effects of ospemifene on OAB symptoms in PMW with VVA. METHODS: Forty PMW suffering from OAB and VVA received oral ospemifene (60 mg/day) for 12 weeks. All patients were assessed with a urodynamic study, a 3-day bladder diary and validated questionnaires (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form [ICIQ-UI SF] and International Consultation on Incontinence Questionnaire - Overactive Bladder [ICIQ-OAB]) at enrollment and at the end of the study. RESULTS: Cytometric capacity, bladder compliance and verbal sensory threshold responses during bladder filling were improved after treatment. The voiding diary showed a significant reduction of daily voids, urge urinary incontinence episodes and nocturnal events. The median overall scores of the ICIQ-UI and ICIQ-OAB were also significantly improved. CONCLUSIONS: Our study suggest that treatment with ospemifene in PMW suffering from OAB is associated with a reduction of OAB symptoms due to a decreased bladder sensitivity and with an improvement in quality of life.


Asunto(s)
Vejiga Urinaria Hiperactiva , Incontinencia Urinaria , Humanos , Femenino , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Posmenopausia , Calidad de Vida , Incontinencia Urinaria/tratamiento farmacológico , Atrofia/tratamiento farmacológico , Resultado del Tratamiento
2.
Climacteric ; 24(6): 531-532, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34169785

RESUMEN

The management of pelvic organ disorders is common and challenging work. Nowadays, midlife women are more active than they were in the past, and the development of pelvic organ prolapse (POP) disrupts quality of life and impairs social and personal activities. The aging process and hormonal changes have a role in influencing the structure and function of the lower urinary and genital tract. Correct diagnosis of pelvic organ disorders and the identification of women's symptoms are the hallmarks of tailored management. Treatment is multimodal and multidisciplinary; it requires competence in pelvic medicine and surgery. When conservative treatments fail, women with symptomatic POP are candidates for reconstructive surgery: the optimal management requires clinicians who are familiar with all of the available strategies and who are able to choose the best strategies in a tailored manner. Knowing and understanding the management of POP should be integrated into the practice of health-care professionals dealing in menopause.


Asunto(s)
Menopausia , Diafragma Pélvico , Calidad de Vida , Envejecimiento , Humanos
3.
Med Hypotheses ; 50(3): 253-7, 1998 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9578330

RESUMEN

Both human cell lines HL-60 and AML-193 exhibit a myeloblastic and promyelocytic morphology, respectively, but may be regarded as bipotent leukemic precursors. They can be triggered to differentiate to either granulocytes or monocytes upon retinoic acid (RA) or 1,25-dihydroxyvitamin D (D3) addition, respectively. We have investigated the effect of combined addition of these chemical inducers on the in-vitro differentiation of both cell lines. RA and D3 added together exert synergistic effects on the in-vitro maturation of these myeloid cell lines. Interestingly, the additive effects were lost if the cells were incubated with the inducers added at sequential times. The synergistic effect could be transposed in vivo and could be clinically significant in the treatment of the promyelocytic leukemia. This clinical strategy may help to prevent retinoic acid resistance or to overcome it in patients relapsed after RA therapy and usually unresponsive to a reinduction therapy with RA alone.


Asunto(s)
Colecalciferol/administración & dosificación , Leucemia Promielocítica Aguda/tratamiento farmacológico , Tretinoina/administración & dosificación , Diferenciación Celular/efectos de los fármacos , Resistencia a Medicamentos , Sinergismo Farmacológico , Células HL-60 , Humanos , Leucemia Promielocítica Aguda/patología , Modelos Biológicos , Células Tumorales Cultivadas
4.
Am J Med Sci ; 315(1): 59-62, 1998 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9427577

RESUMEN

A marked discrepancy between mild and late clinical features and a nearly complete absence of erythrocyte uroporphyrinogen decarboxylase activity (Ery-UROD activity) was observed in a case of inherited porphyria cutanea tarda. The entity and time of appearance of clinical features, the onset of clinical symptoms after exposure to contributing factors, the effectiveness of phlebotomies and heterozygosity of the mother alone for uroporphyrinogen decarboxylase (UROD) deficiency were typical for familial porphyria cutanea tarda (F-PCT), whereas the extremely low UROD activity was peculiar to hepatoerythropoietic porphyria (HEP). These observations indicate that: 1) Ery-UROD activity may not always be useful to discriminate between F-PCT and HEP; 2) Ery-UROD activity does not always correlate with clinical symptoms; 3) in inherited UROD deficiency, the genetic defect may be heterogeneous. Finally, the observed discrepancy may provide additional evidence for the existence of tissue-specific isozymes.


Asunto(s)
Eritrocitos/enzimología , Porfiria Cutánea Tardía/diagnóstico , Porfiria Cutánea Tardía/genética , Uroporfirinógeno Descarboxilasa/sangre , Adulto , Biomarcadores/sangre , Consanguinidad , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Linaje , Porfiria Cutánea Tardía/terapia , Porfirinas/sangre , Porfirinas/orina
5.
Ann Ital Chir ; 64(3): 271-4, 1993.
Artículo en Italiano | MEDLINE | ID: mdl-8109813

RESUMEN

After thyroidectomy, either total or partial, hypocalcaemia can occur in some cases temporary and in other permanent. For explaining transient hypocalcaemia are reported some pathogenetic mechanism can assume particular aspects in hyperthyroid subjects. Permanent hypocalcaemia is substantially due to anatomical lesions to the parathyroid glands. On the other hand, in subjects with hypothyroidism postoperative, a reduced concentration of circulating calcium can coexist with normal values or even elevated of parathormone. The condition of euthyroidism is basic for the resumption of the calcium homoeostasis.


Asunto(s)
Hipocalcemia/etiología , Complicaciones Posoperatorias/etiología , Tiroidectomía/efectos adversos , Humanos , Hipertiroidismo/complicaciones , Hipertiroidismo/cirugía , Hipoparatiroidismo/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...